Picture the question that costs you points: a Black adult, uncomplicated stage 1 hypertension, and an answer choice that starts amlodipine "because thiazides and CCBs are preferred in Black patients." Two years ago that was the keyed answer. Under the guideline that now governs your exam, it is the trap. In August 2025 the AHA and ACC rewrote the blood pressure guideline: a new risk calculator, race out of first-line selection, and a different way to start stage 2. The danger is not that the material is hard. It is that the answer you memorized is now the distractor, and most prep notes still teach the old rule as gospel.
This review gives you the four testable changes, the stable core that did not move, and the exact distractor patterns built from the guidance that just got retired.
Why This Guideline Is Exam-Relevant Now
Read the masthead: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM. The third name is AANP, the body that certifies most FNPs. Your certifier co-authored this document, which moves its content from "eventually testable" to "fair game on your sitting."
Hypertension also sits at the intersection of everything the exam rewards: pharmacology, chronic disease management, screening, and patient education. It shows up in vignettes across adult, geriatric, and reproductive-age patients. Here is the principle to study by, and you only need it once: item banks update on a lag, so most questions are written where old and new guidance still agree. Master the stable core first. Then learn the deltas, because the hardest new items get written at exactly the points where the guideline moved. When two sources conflict, study to the newest national guideline.
What Did Not Change: The Stable Core
Start here, because this is where most of your points live. The BP categories are unchanged: normal is below 120/80, elevated is 120 to 129 with diastolic below 80, stage 1 is 130 to 139 or 80 to 89, and stage 2 is 140/90 or higher. The treatment goal for most adults stays below 130/80. The four first-line drug classes are the same: thiazide-type diuretics, ACE inhibitors, ARBs, and dihydropyridine calcium channel blockers.
- Confirm the diagnosis with proper technique: correct cuff size, seated and rested, an average of two or more readings on two or more occasions, with out-of-office confirmation.
- Lifestyle change stays first-line for everyone: DASH-style diet, sodium reduction, weight loss, aerobic activity, and limiting alcohol.
- Never combine an ACE inhibitor with an ARB.
- Check creatinine and potassium within two to four weeks of starting or titrating an ACEI, ARB, or diuretic.
Get free FNP study tips
The highest-yield FNP prep, in plain English, a few minutes a week.
By subscribing you agree to receive emails from HLT Mastery.
- Weekly, never noisy
- One short email a week — the highest-yield concept to review and a practice question to test yourself.
- No spam, no sharing
- Only prep that actually helps. Unsubscribe in one click, and we never share your email.
The Four Testable Changes
1. PREVENT Replaces the Pooled Cohort Equations
The Pooled Cohort Equations are out; PREVENT is in. PREVENT estimates 10- and 30-year total cardiovascular risk with heart failure included, not just atherosclerotic events, so any answer that reaches for an ASCVD score is reaching for last decade's tool. The decision it drives is the one you already know: a patient with stage 1 hypertension and no clinical CVD, diabetes, or CKD starts medication when 10-year predicted CVD risk hits 7.5 percent or higher. Below that line, stage 1 gets lifestyle therapy and reassessment in three to six months. PREVENT also drops race as an input, which is why the next change follows directly from this one.
2. First-Line Selection Is Race-Neutral
The 2017-era preference for a CCB or thiazide in Black adults without heart failure or CKD is gone. Every patient without a compelling indication can start any of the four first-line classes, chosen on patient-specific factors: CKD, diabetes with albuminuria, pregnancy potential, electrolytes, and cost or adherence. If an answer choice justifies a drug by race alone, that choice is now wrong.
3. Stage 2 Starts With a Single-Pill Combination
For stage 2 hypertension, the guideline now prefers starting two first-line agents as a single-pill, fixed-dose combination, such as an ACE inhibitor with a dihydropyridine CCB, or an ACE inhibitor with a thiazide. The payoff is adherence and faster time to control. The old move of starting one agent and rechecking in a month is no longer the best answer for a patient who walks in at 140/90 or above.
4. Pregnancy: Treat, Do Not Just Observe
Chronic hypertension in pregnancy is now treated to below 140/90, down from the older threshold of 160/110, a shift backed by the CHAP trial showing better maternal and fetal outcomes without compromising fetal growth. Severe-range pressure of 160/110 or higher, confirmed within 15 minutes, requires treatment within 30 to 60 minutes. Preferred agents are labetalol and extended-release nifedipine, with methyldopa as an alternative. ACE inhibitors, ARBs, direct renin inhibitors, and atenolol are contraindicated. Counsel patients with hypertension who are pregnant or planning pregnancy on low-dose aspirin to reduce preeclampsia risk.
How the Exam Turns Old Guidance Into Distractors
Each retired rule becomes a wrong answer that still reads as reasonable. Learn the old rule and the new rule together, and you can watch the trap being set. Here is what each one looks like on the page.
- The race-based selection distractor: a Black adult with uncomplicated stage 1 hypertension, with amlodipine offered because thiazides and CCBs were once preferred in Black patients. Race alone no longer drives selection.
- The monotherapy-first distractor: a patient at 152/94, with one option starting lisinopril alone and a four-week recheck. The keyed answer initiates a single-pill two-drug combination.
- The old-calculator distractor: an option directing you to calculate 10-year ASCVD risk with the Pooled Cohort Equations. Risk now runs through PREVENT, and the stage 1 treatment threshold is 7.5 percent.
- The treat-everyone distractor: an option starting medication for every reading at or above 130/80. Stage 1 without CVD, diabetes, CKD, or elevated PREVENT risk gets lifestyle therapy and reassessment, not a prescription.
Worked Vignette: The 52-Year-Old at 144/92
A 52-year-old woman presents for follow-up. Properly measured office readings average 144/92 today and 146/90 three weeks ago. She has no diabetes, CKD, or known cardiovascular disease, and takes no medications. What is the best initial management?
Walk the chain. Two properly measured averages at or above 140/90 make this stage 2 hypertension, so you do not need a risk calculation to justify drug therapy; the stage itself is the indication. Stage 2 means lifestyle counseling plus pharmacotherapy from the start, and the guideline prefers a single-pill dual-class combination, for example lisinopril-amlodipine or lisinopril-hydrochlorothiazide. Order baseline labs including creatinine, potassium, and a metabolic panel, repeat creatinine and potassium within two to four weeks of starting the ACEI and diuretic, and see her back in about a month, titrating until she holds below 130/80.
Exam pearl: risk calculators decide treatment in stage 1. Stage 2 is its own indication. If the vignette hands you readings at or above 140/90, do not hunt for risk percentages; pick the answer that starts combination therapy alongside lifestyle change.
Compelling Indications You Still Must Know Cold
Compelling indications override the open-choice rule, and they did not change. These pairings stay among the highest-yield hypertension facts on the exam.
| Clinical context | Preferred agent(s) | Why it is tested |
|---|---|---|
| CKD with albuminuria | ACE inhibitor or ARB | Slows progression; classic renal-protection item |
| Diabetes with albuminuria | ACE inhibitor or ARB | Same mechanism; watch for the no-albuminuria twist where any first-line agent works |
| HFrEF | Guideline-directed therapy: ACEI, ARB, or ARNI plus an evidence-based beta-blocker | Avoid non-dihydropyridine CCBs; do not pick verapamil or diltiazem |
| Post-MI or angina | Beta-blocker, usually with an ACEI or ARB | Beta-blockers are not first-line for uncomplicated hypertension, but they are here |
| Pregnancy | Labetalol or extended-release nifedipine; methyldopa as alternative | ACEI, ARB, and renin inhibitors are contraindicated |
Your Next Study Block
Turn this into practice within 24 hours, while the deltas are fresh. Open your question bank, filter to cardiovascular and pharmacology, and run 20 hypertension items. Read every rationale with one question in mind: is this written to the 2025 guideline or the 2017 one? Flag each rationale that fails that vintage test, and write one line on why it is stale. Naming the trap in your own words is the exact discrimination the exam is testing, and it sticks far better than recognizing it on the page.
Then self-check without notes: name the four first-line classes, the stage 1 drug-therapy trigger (7.5 percent), the stage 2 initiation strategy, the pregnancy-safe agents, and the five compelling-indication pairings. Produce those cold and hypertension items stop being a threat and start being banked points.
Run that drill in a cardiovascular set on FNP Mastery, where the rationales are written to the 2025 guideline, so the answer you reason out is the answer that scores.
Frequently Asked Questions
Tap a question to expand the answer. You can leave several open at once.
